The Race to Redefine Wet AMD Treatment Enters Its Decisive Phase

Ocular Therapeutix, EyePoint, and 4D Molecular Therapeutics are attacking the same problem through three platforms: a bioresorbable hydrogel, a sustained-release insert, and a one-time genetic medicine.

Anti-VEGF therapy turned wet age-related macular degeneration from a fast track to severe vision loss into a disease that can be controlled for years. The catch is that control depends on continued treatment. For most patients, that means repeated intravitreal injections, frequent imaging, and a lifelong schedule of retina visits. Trials show what anti-VEGF drugs achieve under consistent dosing. Real-world outcomes trail, because patients miss visits, stop treatment, or are dosed less often than their disease demands.

So the next advance in wet AMD may have less to do with a new way to inhibit VEGF and more to do with keeping that inhibition active longer. Three late-stage programs aim to do exactly that.

Ocular’s AXPAXLI releases the tyrosine kinase inhibitor axitinib from a bioresorbable hydrogel for six months or more. EyePoint’s DURAVYU delivers vorolanib from a bioerodible insert on a six-month cycle. 4DMT’s 4D-150 uses an engineered viral vector to turn retinal cells into a multi-year source of anti-VEGF biologics after a single injection. All three cut treatment burden. They differ in reversibility, redosing, mechanism, clinical maturity, and how much they would change retina practice. That makes the contest more consequential than a race for the longest dosing interval.

AXPAXLI: The First Regulatory Test

Ocular Therapeutix (Nasdaq: OCUL) is closest to filing. AXPAXLI pairs axitinib with the company’s ELUTYX hydrogel, delivered by intravitreal injection and designed to sustain VEGF blockade before it degrades.

In February 2026, the Phase 3 SOL-1 trial in treatment-naive patients met its superiority endpoint. At Week 36, 74.1% of AXPAXLI patients maintained vision under the trial’s definition versus 55.8% on aflibercept; at Week 52, 65.9% versus 44.2%. AXPAXLI was generally well tolerated, with no treatment-related ocular or systemic serious adverse events.

The design matters. SOL-1 did not test AXPAXLI against continuously dosed aflibercept. It compared AXPAXLI with a single aflibercept dose after an anti-VEGF loading phase, which made the study a durability test rather than a conventional non-inferiority comparison against ongoing standard care.

Path to an NDA

The regulatory path is moving fast anyway. After a May 2026 Type C meeting, Ocular said it aligned with the FDA to submit an NDA built primarily on SOL-1 efficacy and safety, plus interim safety from the larger SOL-R trial. It plans the interim in the fourth quarter to establish a database of more than 300 AXPAXLI-treated patients with at least a year of follow-up, then file before year-end. Ocular no longer expects SOL-R efficacy for the initial submission. It intends to keep the study masked through Week 96 to test longer-term differentiation, including potential superiority over aflibercept 8 mg dosed every six months and possible effects on fibrosis and atrophy.

That gives AXPAXLI two objectives: reach the market quickly on SOL-1 and the safety package, then show that prolonged VEGF suppression can do more than cut injections and may improve long-term disease control.

Ocular has the balance sheet to pursue both, reporting $666.7 million in cash at the end of the first quarter of 2026 and a runway into 2028. That figure excludes the full cost of a launch. The near-term question is regulatory: will the FDA accept a filing anchored by one pivotal efficacy study and confirmatory data? The longer-term question is clinical: can AXPAXLI’s durability hold up across a representative population and against actively dosed comparators?

DURAVYU: A Predictable Six-Month Model

EyePoint Pharmaceuticals (Nasdaq: EYPT) is pursuing a different sustained-delivery bet. DURAVYU combines vorolanib, a TKI that blocks VEGF receptors and PDGFR and may affect IL-6 and JAK1 signaling, with the bioerodible Durasert E insert. Rather than reach for annual dosing now, EyePoint is testing a six-month interval in both pivotal trials.

The identical LUGANO and LUCIA studies enrolled more than 900 patients with active wet AMD, treatment-naive and previously treated, randomized to DURAVYU every six months or on-label aflibercept. The primary endpoint is non-inferiority in mean best-corrected visual acuity at Weeks 52 and 56. Secondary endpoints cover retinal anatomy, safety, treatment burden, and the share of patients who stay free of supplemental aflibercept.

The program has drawn three consecutive recommendations from its independent Data Safety Monitoring Committee to continue without modification, and masked safety has tracked the experience across four earlier DURAVYU trials in more than 190 patients. That does not predict success, but it removes one source of uncertainty heading into the readouts.

Built for the Clinic

The model should also be easy to adopt. DURAVYU uses a standard office-based intravitreal procedure and stays scheduled and repeatable, so physicians keep regular chances to reassess disease activity while patients move toward two planned treatments a year. The pitch is not the end of injections. It is a more predictable cadence.

EyePoint reported $223 million in cash and investments at the end of the first quarter, a runway into the fourth quarter of 2027 that clears the Phase 3 milestones, and is scaling manufacturing while advancing DURAVYU in diabetic macular edema. For investors, the question is whether six-month dosing preserves acuity as well as aflibercept while cutting rescue treatment. For clinicians, the fine print matters as much as the interval: a six-month label is most valuable if fluid stays controlled throughout and few patients need supplemental injections.

4D-150: The Most Ambitious Durability Claim

4D Molecular Therapeutics (Nasdaq: FDMT) is attempting the sharpest break from repeated dosing. 4D-150 uses the company’s engineered R100 adeno-associated viral vector to deliver genetic instructions for sustained expression of aflibercept and an anti-VEGF-C molecule inside the retina. The goal is to make the eye its own continuing source of anti-VEGF therapy after one injection, with supplemental aflibercept used only when disease activity requires it.

The upside is large, and so is the complexity. A biodegradable insert can simply exhaust its supply. Gene expression persists by design, which puts more weight on inflammation, variability in expression, long-term activity, and the ability to manage patients whose response is insufficient or hard to tolerate. Upcoming two-year data from the Phase 2b PRISM study should bridge earlier results and the pivotal program. Clinicians will watch not just the share of patients who avoid supplemental injections, but whether acuity and anatomy hold as follow-up lengthens.

The Pivotal Program

Both Phase 3 trials have completed enrollment. The North American 4FRONT-1 randomized 523 treatment-naive patients; the global 4FRONT-2 closed enrollment roughly four months early and should exceed 500 after over-enrollment. Both compare 4D-150 with aflibercept 2 mg every eight weeks, with a non-inferiority primary endpoint in mean BCVA at 52 weeks and a key secondary measuring the reduction in supplemental aflibercept. Topline 4FRONT-1 data should arrive in the first half of 2027, 4FRONT-2 in the second half. Fast enrollment signals investigator and patient interest; it does not answer the efficacy and safety questions.

4DMT reported roughly $458 million in cash, equivalents, and marketable securities at the end of the first quarter and a runway into the second half of 2028, enough to carry both wet AMD readouts and continued work in diabetic macular edema. 4D-150 may offer the most disruption to the current model and may face the highest bar. Non-inferiority alone may not establish the value of a multi-year genetic intervention; the program will likely need a large, durable, and dependable cut in supplemental treatment to justify the added complexity of gene delivery.

Three Platforms, Three Definitions of Success

Grouping these programs as injection-reducers obscures how different they are. AXPAXLI is a bioresorbable axitinib hydrogel targeting six to twelve months of control and nearing an NDA. DURAVYU is a scheduled vorolanib insert tested directly against continuously dosed aflibercept in two large non-inferiority studies. 4D-150 is a genetic medicine built for multi-year anti-VEGF expression after one dose.

Their bars differ accordingly. AXPAXLI needs regulatory acceptance on SOL-1 and its safety exposure, then durable differentiation from SOL-R against higher-dose, actively dosed aflibercept. DURAVYU needs to hold vision and anatomy across a broad population with limited rescue and a clean safety profile. 4D-150 needs proof that one-time genetic delivery produces durable, controllable activity without management burdens that outweigh the fewer injections.

They may also serve different patients. Some retina specialists will prefer the control and reversibility of a repeatable implant; others will value annual or multi-year treatment most for patients at high risk of non-adherence. Disease severity, response to loading, fluid patterns, and preference could all steer selection, and the market may support more than one durable option.

What Comes Next

The milestones are unusually concentrated. Ocular plans to file the AXPAXLI NDA in the fourth quarter of 2026. EyePoint is approaching the LUGANO and LUCIA readouts. 4DMT expects two-year PRISM data before both 4FRONT results in 2027. The decisive metrics will run past the advertised interval to visual acuity, anatomical control, rescue rates, inflammation, and consistency across patient groups. Investors will weigh those against regulatory clarity, manufacturing, and commercial readiness.

Wet AMD no longer lacks effective treatment. It lacks a model that delivers trial-level disease control across a patient’s life. AXPAXLI, DURAVYU, and 4D-150 each aim to close that gap. The next two years should show whether the answer is a degradable hydrogel, a scheduled insert, a one-time genetic medicine, or some combination of the three.

For informational purposes only. Not investment advice or a recommendation to buy or sell any security. Company forward-looking statements are subject to the risks described in their SEC filings.